Comparable stake leader
KKR Genetic Disorder L.P.
SEC ownership of BridgeBio Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001743881.
Disclosed value leader
Kohlberg Kravis Roberts & Co. L.P.
Comparable rows
50/50
Latest evidence
22 May 2026
- Public ticker
- BBIO on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
KKR Genetic Disorder L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
KKR Genetic Disorder L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
22 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001743881
- Issuer location
- Palo Alto, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BridgeBio Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
KKR Genetic Disorder L.P.
Disclosed value leader
Kohlberg Kravis Roberts &...
Comparable rows
50/50
Latest evidence
22 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 7%
13D/G row: KKR Genetic Disorder L.P.
Showing 1-8 of 50 holder rows.
Quick read
KKR Genetic Disorder L.P. leads the comparable SEC ownership view at 7%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens KKR Genetic Disorder L.P.'s linked filing trail.
Comparable ownership
Top 5
KKR Genetic Disorder L.P.
7%
JANUS HENDERSON GROUP PLC
6.8%
VIKING GLOBAL INVESTORS LP
6.1%
Farallon Capital Partners, L.P.
5.2%
Neil Kumar
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
10%+ Owner
|
7%
|
$476,864,517
13,260,971 shares
|
-$215,760,000 | 12 May 2025 |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
6.8%
from 13D/G
|
$978,607,712
13,179,013 shares
|
— | 31 Mar 2026 |
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
13F
10%+ Owner · Company
|
6.1%
|
$880,129,695
11,842,434 shares
|
-$87,989,901 | 31 Mar 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
5.2%
|
$674,408,855
10,226,063 shares
|
$0 | 22 May 2026 |
| Neil Kumar |
13D/G
3/4/5
Chief Executive Officer, Director
|
4.6%
|
$689,354,243
9,282,982 shares
|
-$87,903,790 | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
1.1%
from 13D/G
|
$286,232,000
4,239,544 shares
mixed-class rows
|
— | 31 Mar 2026 |
| Thomas Trimarchi |
3/4/5
President and CFO
|
0.18%
|
$23,689,095
359,194 shares
|
-$5,991,774 | 16 May 2026 |
| Maricel Apuli |
3/4/5
Chief Accounting Officer
|
0.07%
|
$9,609,318
129,401 shares
|
-$507,018 | 16 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$137,793,138.
Buys
$0
Insiders: 0
Sells
$137,793,138
Insiders: 11
Net
-$137,793,138
Shares: -2,244,728
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 2,244,728
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 426,361 | $0 | $29,395,819 | -$29,395,819 |
| 3-6 | 0 | 393,239 | $0 | $27,789,617 | -$27,789,617 |
| 6-9 | 0 | 707,215 | $0 | $46,383,127 | -$46,383,127 |
| 9-12 | 0 | 717,913 | $0 | $34,224,575 | -$34,224,575 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to BridgeBio Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
VIKING GLOBAL INVESTORS LP
Net 12M change
-$136,091,737
Latest report
22 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $816,436,500 | Filing P/S | 27 Jun 2025 | ||
| KKR Genetic Disorder L.P. | 10%+ Owner | $453,525,208 | Filing P/S | 12 May 2025 | ||
| Neil Kumar | Chief Executive Officer, Director | $357,451,091 | -$67,948,371 | -16% | Mixed | 04 Jun 2026 |
| Charles J. Homcy | Director | $68,309,991 | -$13,912,443 | -17% | Median | 22 Jun 2026 |
| Frank Mccormick | Director | $56,975,538 | -$17,246,737 | -23% | Median | 22 Jun 2026 |
| Thomas Trimarchi | President and CFO | $23,689,095 | -$5,991,774 | -20% | Filing P/S | 16 May 2026 |
| Ali J. Satvat | Director | $12,622,937 | Median | 22 Jun 2026 | ||
| Maricel Apuli | Chief Accounting Officer | $9,609,318 | -$507,018 | -5% | Median | 16 May 2026 |
| James C. Momtazee | Director | $7,356,938 | Median | 22 Jun 2026 | ||
| Brian C. Stephenson | CFO and Treasurer | $6,443,801 | Mixed | 25 Feb 2025 | ||
| Andrew Lo | Director | $5,098,839 | -$6,319,662 | -55% | Median | 22 Jun 2026 |
| Richard H. Scheller | Director | $2,421,359 | Mixed | 16 Feb 2023 | ||
| Douglas A. Dachille | Director | $2,270,796 | Median | 22 Jun 2026 | ||
| Fred Hassan | Director | $2,218,814 | Median | 22 Jun 2026 | ||
| Andrea Ellis | Director | $1,676,716 | -$5,052,485 | -75% | Median | 22 Jun 2026 |
| Ronald J. Daniels | Director | $1,558,049 | -$3,888,999 | -71% | Median | 22 Jun 2026 |
| Randal W. Scott | Director | $1,098,071 | -$2,092,477 | -66% | Mixed | 15 May 2026 |
| Eric Aguiar | Director | $785,596 | Median | 22 Jun 2026 | ||
| Hannah Valantine | Director | $664,444 | -$4,367,344 | -87% | Mixed | 22 Jun 2026 |
| Jennifer E. Cook | Director | $586,810 | -$8,764,427 | -94% | Filing P/S | 22 Jun 2026 |
Recent insider transactions for BridgeBio Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer E. Cook | BBIO | Common Stock | Sale | -81.6% | $2,601,690 | $70.00 | -37,167 | 8,383 | 24 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Options Exercise | 443.4% | 37,167 | 45,550 | 24 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Options Exercise | -68.4% | -37,167 | 17,167 | 24 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -20.8% | $150,580 | $68.57 | -2,196 | 8,383 | 23 Jun 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Sale | -19.2% | $150,580 | $68.57 | -2,196 | 9,259 | 23 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Hannah Valantine | BBIO | Common Stock | Sale | -19.7% | $190,944 | $68.00 | -2,808 | 11,455 | 22 Jun 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Options Exercise | 24.5% | 2,808 | 14,263 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Common Stock | Award | 53.4% | 3,990 | 11,455 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Options Exercise | -33.3% | -2,808 | 5,617 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Andrew Lo | BBIO | Common Stock | Award | 28.3% | 3,990 | 18,079 | 22 Jun 2026 | Direct | ||
| Andrew Lo | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Charles J. Homcy | BBIO | Common Stock | Award | 0.44% | 3,990 | 919,876 | 22 Jun 2026 | Direct | ||
| Charles J. Homcy | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Eric Aguiar | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Eric Aguiar | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Ronald J. Daniels | BBIO | Common Stock | Award | 23.5% | 3,990 | 20,981 | 22 Jun 2026 | Direct | ||
| Ronald J. Daniels | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Andrea Ellis | BBIO | Common Stock | Award | 21.5% | 3,990 | 22,579 | 22 Jun 2026 | Direct | ||
| Andrea Ellis | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Fred Hassan | BBIO | Common Stock | Award | 15.4% | 3,990 | 29,879 | 22 Jun 2026 | Direct | ||
| Fred Hassan | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| James C. Momtazee | BBIO | Common Stock | Award | 26.5% | 3,990 | 19,070 | 22 Jun 2026 | Direct | ||
| James C. Momtazee | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Frank Mccormick | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Frank Mccormick | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Douglas A. Dachille | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Douglas A. Dachille | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Ali J. Satvat | BBIO | Common Stock | Award | 2.4% | 3,990 | 169,983 | 22 Jun 2026 | Direct | ||
| Ali J. Satvat | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Charles J. Homcy | BBIO | Common Stock | Tax liability | -0.09% | -788 | 915,886 | 20 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -93.2% | $6,012,157 | $66.62 | -90,240 | 6,589 | 15 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Options Exercise | 604.7% | 83,088 | 96,829 | 15 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Options Exercise | -70.8% | -83,088 | 34,334 | 15 Jun 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Sale | -0.46% | $1,357,538 | $67.88 | -20,000 | 4,318,447 | 05 Jun 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -3.73% | $1,357,540 | $67.88 | -20,000 | 515,686 | 05 Jun 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -0.46% | $1,349,105 | $67.46 | -20,000 | 4,338,447 | 04 Jun 2026 | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -3.6% | $1,349,106 | $67.46 | -20,000 | 535,686 | 04 Jun 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -9.69% | $1,812,522 | $69.44 | -26,103 | 243,327 | 21 May 2026 | Direct |
| Thomas Trimarchi | BBIO | Common Stock | Sale | -3.66% | $888,419 | $65.08 | -13,651 | 359,194 | 18 May 2026 | Direct |
| Thomas Trimarchi | BBIO | Common Stock | Tax liability | -5.76% | -22,781 | 372,845 | 16 May 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Tax liability | -11.8% | -36,236 | 269,430 | 16 May 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Options Exercise | 30.4% | 71,215 | 305,666 | 16 May 2026 | Direct | ||
| Neil Kumar | BBIO | Restricted Stock Units | Options Exercise | -42.1% | -71,215 | 97,794 | 16 May 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Tax liability | -3.51% | -4,714 | 129,401 | 16 May 2026 | Direct | ||
| Randal W. Scott | BBIO | Common Stock | Sale | -46.3% | $671,456 | $67.15 | -10,000 | 11,589 | 15 May 2026 | Direct |
| Randal W. Scott | BBIO | Common Stock | Options Exercise | 86.3% | 10,000 | 21,589 | 15 May 2026 | Direct | ||
| Randal W. Scott | BBIO | Stock Option (Right to Buy) | Options Exercise | -31.8% | -10,000 | 21,501 | 15 May 2026 | Direct |
* marks a reported price that did not pass the local price check.